摘要
左米那普仑缓释胶囊在2013年7月被美国国家食品药物监督管理局批准上市,用于抑郁症的治疗。左米那普仑作为米那普仑的活性异构体,属于5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRI)。与SNRI类其他药物相比,左米那普仑抑制去甲肾上腺素转运体的能力更强。一些临床研究已经表明左米那普仑安全性、耐受性较好且疗效优于安慰剂。因此,在对当前抗抑郁药治疗无效或不能耐受时,左米那普仑能为我们提供一个新的选择。本文就左米那普仑的药理作用、药动学、临床疗效、安全性、耐受性等方面进行综述。
In July 2013, the US Federal Drug Administration （FDA） approved levomilnacipran extended release for the treatment of major depressibve disorder （MDD） in adult patients. Levomilnacipran, the more active enantiomer of milnacipran, is a potent and selective serotonin norepinephrine reuptake inhibitor. In contrast with other selective serotonin norepinephrine reuptake inhibitors, it has greater selectivity for inhibiting norepinephrine reuptake than serotonin reuptake. In clinical trials, levomilnacipran was generally safe and well tolerated. In addition, it has been shown to be more effective than placebo. As a result, levomilnacipran is a new choice especially for the MDD patients who either don＇ t respond to or don＇ t tolerate current antidepressants. The aim of this review was to review the mechanism of action, pharmacodynamics, pharmacokinetics, clinical efficacy, and safety and tolerability of levomilnacipran in this paper.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2015年第6期418-422,共5页
Chinese Journal of New Drugs and Clinical Remedies
